Adults diagnosed with autoimmune rheumatic diseases face a significantly higher risk of developing long COVID following a SARS-CoV-2 infection compared to the general population, according to a large US analysis published in Arthritis & Rheumatology. Researchers found that patients managing these chronic conditions experienced persistent post-infection symptoms at nearly double the rate of matched control patients, highlighting a distinct vulnerability within this patient group.
Retrospective Cohort Study Tracks 187,106 Patients Across US Health Systems
Investigators assembled a retrospective cohort using data from the National Clinical Cohort Collaborative (N3C) to examine the prevalence of long COVID among adults with autoimmune rheumatic diseases, or AIRD. The study evaluated patients with a first documented SARS-CoV-2 infection between September 2021 and December 2023, tracking clinical outcomes through December 2024. Researchers defined long COVID using official International Classification of Diseases (ICD-10) diagnostic codes under U09.9 or via documented visits to specialized long COVID clinics occurring 28 to 365 days after the initial infection.
To establish a reliable comparison, the team used 1:1 nearest-neighbour propensity score matching on age, alongside exact matching on sex, race and ethnicity, SARS-CoV-2 variant-dominant periods, and the specific data-contributing organization. Within the resulting matched cohort of 187,106 adult patients, documented long COVID occurred in 2.8% of individuals with AIRD, compared with 1.5% of matched control patients without autoimmune rheumatic conditions. Multivariable analyses established an adjusted hazard ratio of 1.56, with a 95% confidence interval ranging from 1.45 to 1.67, confirming that AIRD status independently elevates the risk of prolonged post-viral illness.
Treatments and Severe Illness Raise Long-Term Risks
Within the autoimmune cohort, investigators identified several specific clinical factors and treatment exposures linked to an increased likelihood of developing persistent symptoms. Patients exhibiting higher acute COVID-19 severity during their initial infection faced a greater risk of long-term complications. Pre-existing pulmonary disease, obesity, and specific diagnoses such as Sjögren’s syndrome also emerged as notable risk factors within the analysis.
Regarding medical management, the study pointed to patient exposure to rituximab or glucocorticoids as factors associated with an elevated risk of long COVID. However, MDLinx reported that these findings cannot establish whether specific medications directly caused long COVID or serve as a justification for stopping effective baseline therapies. Because case identification relied strictly on diagnostic coding and clinic attendance, the reported percentages also do not capture the full burden of persistent symptoms experienced by patients outside of formal clinical tracking.
Differential Diagnosis Challenges Clinicians Managing Post-COVID Symptoms
The overlap between persistent viral symptoms and underlying rheumatic disease flares creates distinct diagnostic hurdles for treating physicians. When patients present with fatigue, brain fog, and a sharp drop in stamina following an infection, clinicians must determine whether the underlying autoimmune condition is flaring or if long COVID is driving the clinical change. Separate Yale-led research cited by MDLinx adds biological context, showing that antibodies from some long COVID patients attacked brain and nerve tissues in experimental models, suggesting an autoimmune contribution in a subset of individuals.
To untangle these overlapping presentations, study authors and clinical commentators recommend that rheumatologists systematically review patient baselines during follow-up appointments. Physicians can initiate the evaluation by asking patients what has failed to return to normal since their initial viral infection, specifically addressing stamina, cognitive clarity, and daily functional changes. Maintaining long COVID on the differential diagnosis alongside routine disease activity assessments helps guide appropriate care without automatically attributing every new symptom to the baseline rheumatic condition.
Frequently Asked Questions About Rheumatic Disease and Long COVID
What was the primary data source used for the rheumatic disease study?
Researchers utilized data from the National Clinical Cohort Collaborative (N3C) to conduct their retrospective cohort analysis of adult patients across the United States. This repository allowed investigators to match 187,106 patients based on age, sex, race, ethnicity, viral variant periods, and contributing health organizations.
How did investigators identify long COVID cases in the patient cohort?
Cases were identified using the International Classification of Diseases, 10th Revision, Clinical Modification code U09.9 or through documented visits to a dedicated long COVID clinic occurring between 28 and 365 days after the initial SARS-CoV-2 infection.
What did separate Yale-led research discover about antibodies in patients?
Investigators found that antibodies extracted from certain long COVID patients attacked brain and nerve tissues when transferred into healthy mice. This transfer produced increased pain sensitivity, fatigue, impaired balance, and small nerve fiber damage in the animal models.
Keep reading